



Vita Life Sciences Limited  
ABN 35 003 190 421  
Suite 650  
1 Queens Road Melbourne  
Victoria 3004 Australia  
T 61 3 9828 0500  
F 61 3 9820 5957  
[www.vitalifesciences.com](http://www.vitalifesciences.com)

6 August 2015

Dear Shareholder,

### **Full year results guidance**

Vita Life Sciences Ltd (ASX: VSC) today announces that it has revised its sales and EBIT guidance for the financial year ending 31 December 2015 (FY15).

In February 2015 the company provided guidance of sales of circa \$40m with margins similar to those achieved in 2014, implying an EBIT of circa \$7.5m.

Based on preliminary unaudited numbers to 30 June 2015 and revised forecast for FY15 Directors provide:

- Sales guidance circa \$38m
- EBIT guidance circa \$5.5m

Within the company's portfolio of businesses, it has three established markets - Australia, Singapore and Malaysia. Australia and Singapore are trading ahead of 2014 PCP however Malaysia's results have been impacted by challenging economic conditions and the introduction of the GST in April, and these have outweighed the positive impact from Australia and Singapore.

Our portfolio of new businesses has been impacted by:

- product regulation in China;
- ongoing poor performance in Thailand; and
- the impact of start up costs in Indonesia as it readies first sales in Q4 2015.

### **Strategic Initiatives**

The company continues to adapt to the difficult trading conditions in Malaysia and maintain market share. In China we are in the process of introducing cross border e-commerce platforms based out of Singapore and Australia.

In Thailand, following two years of retraction, a new senior management team is being established to make a fresh start.

**Dividend outlook**

The company expects to announce half year results in late August. It is the intention of the company to maintain an interim dividend of 1.5c per share.

Yours faithfully,  
**Vita Life Sciences Ltd**

Matthew Beckett  
Company Secretary